Loading…
Employees: 5,081
Size Cofoe Medical Technology (1187.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $798M, the 648th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$27.66 on 6 Nov 2026.
Performance Over six months the shares fell 27.0%, against -7.3% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 40.2% over the last twelve months (peer median +9.1%); the operating margin is 9.9% (peer median 10.8%).
Valuation It trades at 12.5× forward earnings against a peer median of 20.3× (2nd cheapest of 14).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.9 points above its cost of capital (7.8% WACC).
Next results Next results expected around 4 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$4.75B | HK$3.66B | HK$3.23B | HK$3.14B | HK$3.45B |
| Revenue growth | — | +13% | +3% | -9% | — |
| Gross profit | HK$2.69B | HK$1.79B | HK$1.54B | HK$1.24B | HK$1.27B |
| EBITDA | n/a | HK$573M | HK$532M | HK$405M | HK$437M |
| Net income | HK$472M | HK$403M | HK$338M | HK$281M | HK$351M |
| Free cash flow | HK$297M | HK$604M | HK$604M | HK$70.9M | -HK$555M |
| Capital expenditure | HK$163M | HK$193M | HK$131M | HK$412M | HK$744M |
| Total debt | HK$1.56B | HK$1.02B | HK$1.07B | HK$820M | HK$648M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1187.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.4% | -3.6% | 9th highest of 21 |
| 6-month return | -27.0% | -7.3% | 3rd lowest of 21 |
| Distance from 52-week high | -32.5% | -28.7% | 8th lowest of 21 |
| Revenue growth (TTM) | +40.2% | +9.1% | 2nd highest of 21 |
| Operating margin | 9.9% | 10.8% | 11th highest of 21 |
| Forward P/E | 12.5× | 20.3× | 2nd cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | -8.0% | 5.5% | 2nd least demanding of 12 |
| Growth delivered (Del g) | +6.6% | +15.6% | 3rd lowest of 12 |
| Hurdle (Req g minus delivered) | -14.6 pp | -13.9 pp | 6th least demanding of 12 |
| ROIC minus cost of capital | +4.9 pp | +0.1 pp | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cofoe Medical Technology 1187.HK | Hong Kong | $798M | -27% | +40% | 10% | 12.5× | -8.0% | +6.6% |
| Allmed Medical Products 002950.SZ | China | $798M | -39% | +14% | 8% | n/a | n/a | n/a |
| Standard Engineering Technology SETL.NS | India | $796M | +164% | +26% | 13% | n/a | n/a | n/a |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $806M | -25% | +39% | 26% | 30.0× | 21.1% | +24.2% |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $784M | -25% | +35% | 21% | 17.8× | -2.1% | +23.5% |
| Varex Imaging VREX | United States | $783M | -10% | +5% | 8% | 20.3× | n/a | n/a |
| Maccura Biotechnology 300463.SZ | China | $814M | -14% | -1% | -4% | 164.7× | 9.2% | -10.2% |
| BMC Medical 301367.SZ | China | $780M | -13% | +37% | 17% | 19.8× | 0.1% | +15.6% |
| Advanced Medical Solutions AMS.L | United Kingdom | $824M | +14% | +6% | 12% | 20.7× | 19.6% | +21.4% |
| Hangzhou Biotest Biotech 688767.SS | China | $824M | +5% | -4% | 3% | 34.7× | n/a | n/a |
| OrthoPediatrics KIDS | United States | $829M | +78% | +16% | -8% | n/a | n/a | n/a |
| InMode INMD | United States | $767M | -5% | -7% | 18% | 10.1× | -10.5% | +12.4% |
| Beijing Aerospace Changfeng 600855.SS | China | $832M | -35% | -10% | -19% | n/a | n/a | n/a |
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | n/a | n/a | n/a |
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 24.5× | -2.4% | +15.7% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | n/a | 33.5% | -0.6% |
| Shenzhen Lifotronic Technology 688389.SS | China | $749M | -11% | +14% | 13% | 32.4× | 13.5% | +13.3% |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $851M | -13% | +39% | 25% | 15.9× | 5.5% | +105.8% |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | n/a | n/a | n/a |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 19.3× | n/a | n/a |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 16.1× | -2.1% | +11.8% |